BMC Cancer 18 , 784 (2018)
"There aren't that many other substances people are injecting into themselves where you see that the clinical evidence is so lacking." But the panel of outside advisers convened for the meeting includes at least seven doctors or pharmacists with financial ties to the peptide industry
HUBERMAN: While I'm not opposed to that approach, you just want to make sure that the dosing, or I should say the relative dosing of each peptide is such that, you know, You're avoiding unnecessary increases in prolactin and cortisol, and that you're not hitting a pathway redundantly
The need of the hour is to have more randomized, double-blind, placebo-controlled trials with a larger sample size, long term follow-up period, with well defined primary and secondary outcomes, targeted to evaluate the efficacy and safety of the skin-lightening effects of topical, oral and parenteral glutathione
Therapeutic Adv
(PubMed) Lack of regulatory oversight : Because intravenous glutathione for cosmetic use is generally unapproved, many treatments are unregulated or done in non-medical settings increasing danger
